Author: Qualsera

A data-driven analysis of potency, purity, and manufacturing consistency across the peptide market.

As peptide products become more widely accessible, consistency in manufacturing and labeling becomes increasingly important. This report provides a reference framework for understanding how products perform relative to commonly applied quality benchmarks.

Key Findings:

• A significant portion of tested products fell outside a 90–110% potency range
• Upward bias in label claim was observed across multiple peptide categories
• Purity levels were generally high, but with a measurable tail below 98%
• Variability across suppliers indicates uneven manufacturing consistency
• Sterility and endotoxin testing identified variability in aseptic control

Why This Matters:

As peptide products become more widely accessible, consistency in manufacturing and labeling becomes increasingly important. This report provides a reference framework for evaluating how products perform relative to commonly applied quality benchmarks.

What’s Inside the Report:

• Potency distribution across major peptide categories
• Purity analysis relative to specification thresholds
• Process capability and variability trends
• Sterility and endotoxin observations
• Year-over-year comparison (2024 vs 2025)

About the Data:

This report is based on anonymized laboratory testing data collected during routine quality control activities. Results reflect observed variability within tested samples and are not intended to represent individual suppliers.

About Qualsera

Qualsera is an independent certification body focused on improving transparency and consistency in the peptide market through data-driven quality standards and verification.

More than a paid checkmark.

Below is a general outline of the process that peptide manufacturers can expect to follow in order to achieve Qualsera Certification.

Step 1: The Interview

First, Qualsera will schedule an appointment to interview a potential certification client. During the interview, we will ask questions about their operations, their procedures, and their business in order to gauge if they have the resources and commitment to quality necessary to achieve and maintain certification.

It is also an opportunity for them to ask questions about Qualsera, the certification process, etc.

Step 2: The Engagement

If both parties agree that certification is in their best interest, the next step is the contractual agreement. The manufacturer will sign an agreement that outlines the requirements for Qualsera Certification, including but not limited to:

• Annual on-site audits against current FDA Good Manufacturing Practices (cGMP) for drugs, including reviews of all available procedures and controls
• Formulation testing to ensure accurate identify, potency, sterility, and endotoxin levels of all products within the scope of the Qualsera Certification
• Periodic process capability study & analysis of all manufacturing lines that produce products within the scope of the Qualsera Certification
• Change control review requirements. If any of the manufacturing processes or formulations change, they are required to undergo any pertinent revalidations before they are implemented
• Corrective and Preventative Action (CAPA) follow-up. If any quality requirement is not met, the manufacturer must submit effective CAPA or risk certification revocation. If Qualsera Certification is revoked, the Qualsera QS Certification Mark & Number must be removed from all products and literature until the certificate is reinstated.

Step 3: On-site Audit

Qualsera will send a knowledgeable auditor to the manufacturer’s facility for an inspection per 21 CFR 210/211 current Good Manufacturing Practices (cGMP) requirements for drug products.

Given the current state of peptide manufacturing, grading will be assigned relative to industry peers, and any Critical findings require resolution via CAPA before certification can proceed.

During the visit, all production lines intended to be in scope of the certification will be identified and documented.

Step 4: Formulation & Process Audit

All products the manufacturer intends to certify will be submitted to an independent laboratory for analysis. The laboratory will test the identity, potency, purity, sterility, endotoxin level, and other quality attributes for the products. This testing will validate that the formulation is acceptable for certification. If the formulation is not acceptable, CAPA will be issued and required to be resolved prior to certification.

Next, the potency (label claim) data will be used to determine process capability: how well can the manufacturing line and process ensure accurate repeatable potency label claim, and what are the defect rates for subpotent and hyperpotent products. If process capability is not acceptable, CAPA will be issued and required to be resolved prior to certification.

Step 5: Certification

If all requirements are met and any CAPA successfully resolved, Qualsera will issue Qualsera Certification with a certification number to the manufactures. This allows the manufacturer to use the Certification Mark and Certification Number on any materials, including product labels of products within the scope of the certification.

Consumers can verify the manufacturer’s certification status at our website using the certificate number on any literature or printed on the product.

The consumer peptide market has experienced massive growth in the last two years. The market is currently valued in the billions, and is expected to have a compound annual growth rate (CAGR) of 10.4% over the next decade.

This massive opportunity has led to an explosion of suppliers in the space, all at very different levels of quality and quality control, creating a caveat emptor market, where the burden is entirely on the consumer to ensure that the quality of the product is acceptable for use.

Anyone that works in the quality assurance and control space knows that you cannot ‘test’ quality into a product. Design and manufacturing controls are critical to consistent, reproducible quality. Quality is built in before a product is ever made.

Qualsera is entering the peptide market at the right time. There are two critical needs in the consumer peptide market today:

Quality assurance and control must be advanced to give consumers confidence in peptide products. Consumers are not able to identify all of the risks in products, much less continue to bear the burden of performing shipment by shipment testing for an incomplete view of the safety and efficacy of their products.

Legitimate peptide manufacturers who invest in their processes and quality control need to be able differentiate themselves from the ’email resellers’ of sub-par peptides in the market. There is no appetite to invest in quality assurance and quality control when the only difference a consumer sees is a logo on a Certificate of Analysis and a test value.

Our vision solves both of these issues. Partnering with manufacturers and distributers in a certification body-style relationship raises the stakes. The reputational risks of poor quality events fall on both the manufacturer as well as Qualsera.

This means Qualsera must be intentional about partnering with peptide manufacturers who are investing in quality assurance & quality control, and are committed to supplying the highest quality peptides to their customers.

Certification is an ongoing process, with periodic product auditing and annual GMP audits. At any time, Qualsera can pull certification from a manufacturer if they do not invest in resolving issues in a thorough and timely manner.

In our vision, consumers would never need to test a product from a manufacturer with an active Qualsera certification. They can trust in the oversight provided by the Qualsera certification program and the testing produced internally by the manufacturer – much like they do with pharmaceutical drugs in the US market today.

The peptide market is ready to move to the next level by investing in sustainable quality assurance and control practices – and Qualsera stands ready as a partner to help it make the transition.